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Abstract
Objective To identify determinants for the discontinuation
of non-ergoline dopamine agonist (DA) treatment in
patients with Parkinson’s disease (PD) and to identify
genetic determinants in genes encoding dopamine receptor
(DR)D2 and DRD3 in a exploratory analysis.
Methods Patients included were first-time users of the non-
ergoline DA ropinirole or pramipexole who had been
diagnosed with PD before 2005. Treatment discontinuation
was defined as a gap of 180 days or more between two refills
oftheDA.Non-geneticdeterminantsfordiscontinuationwere
studied in the overall population, and genetic determinants
[DRD2 141C Ins/Del, DRD2 (CA)n STR, DRD2 TaqIA,
DRD3 MscI single nucleotide polymorphism (SNP) and
DRD3 MspI SNP] were studied in a subgroup. Cox propor-
tional hazard analysis was used to estimate the hazard ratios
(HR) for the discontinuation of non-ergoline DA treatment.
Results The study population comprised 90 patients.
Apomorphine use was associated with non-ergoline DA
discontinuation, although the apomorphine group consisted
only of three patients [HR 6.26; 95% confidence interval
(CI) 1.85–21.2]. Daily levodopa dosages between 500 and
1000 mg were positively associated with discontinuation
(HR 2.31; 95% CI 1.08–4.93). Included in the exploratory
pharmacogenetic analysis were 38 patients. The absence of
a 15× DRD2 CA repeat allele was significantly related with
a decreased discontinuation of non-ergoline treatment (HR
0.23; 95% CI 0.07–0.81). The DRD3 MspI polymorphism
showed a non-significant allele dose effect, suggestive of a
causal relationship.
Conclusion This study identified apomorphine use and
levodopa dosages between 500 and 1000 mg as non-
genetic and the 15× DRD2 CA repeat allele as genetic
determinants for the discontinuation of non-ergoline DA
treatment in patients with PD. More research is needed to
replicate these findings.
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Introduction
Long-term treatment with levodopa, which is still consid-
ered to be the gold standard for the pharmacotherapeutic
management of patients with Parkinson’s disease (PD),
often leads to motor complications, such as wearing-off and
dyskinesias [1]. As a result, dopaminergic therapy with
dopamine agonists (DA) has gained popularity as initial
therapy in younger patients and as add-on therapy in older
individuals. However, it has been demonstrated that in
clinical practice over half of patients initiating non-ergoline
DA ropinirole and pramipexole therapy have discontinued
(51 and 60%, respectively) within 3 years [2].
Remarkably, determinants for the discontinuation of
non-ergoline DA therapy are largely unknown. We hypoth-
esize that several non-genetic factors, such as the duration
of PD or concurrent drug use, are associated with this
discontinuation of non-ergoline DA use. We also suggest
that genetic polymorphisms in the genes encoding the
dopamine receptor (DR) are associated with this discontin-
uation. Several polymorphisms in the DR have been
identified [3–7], and those in DRD2 and DRD3 could be
important determinants because the non-ergoline DA have
high binding characteristics for the DRD2 subgroup and a
preferential affinity for the DRD3 subgroup.
The aim of this study was to identify non-genetic
determinants for the discontinuation of non-ergoline DA
and to perform an exploratory analysis of genetic determi-
nants in genes encoding DRD2 and DRD3.
Methods
Setting, study population and data collection
The setting of this cohort study was the neurology
department of a large teaching hospital in Enschede, The
Netherlands. Outpatients diagnosed with PD before 2005
who had received a non-ergoline DA (ropinirole or
pramipexole) for the first time were included. Prescription
data were retrieved from community pharmacies after
obtaining the patients’ informed consent as described in
an earlier publication [2]. The date of the first prescription
of the DA was defined as the index date. To ascertain first-
time use, we required that the patients had at least 180 days
of prescription history for any prescribed drug before the
index date. In addition, patients needed to have at least
180 days of prescription data for any medicine after the
index date. Thereafter, patients were asked for informed
consent in order to obtain saliva for DNA collection and
pharmacogenetic analysis. All genotyped patients were of
Caucasian ethnicity. The patients included in the genetic
analysis were asked in a semi-structured interview by a
researcher (MA) if they could recollect any period in which
they had discontinued non-ergoline DA treatment and, if so,
what was the reason for this discontinuation. The study was
approved by the medical ethics committee.
Endpoint
The endpoint of this study was discontinuation of non-
ergoline DA treatment. Patients were considered to have
discontinued ropinirole or pramipexole treatment when more
than 180 days elapsed between two consecutive pharmacy
refills of the non-ergoline DA. Patients who persisted with
therapy to the end of their observation time were censored
on the last day of their follow-up. Consequently, patients
who were lost to follow-up (e.g. moved to another place or
died) were censored on the last day of their follow-up.
Determinants
Non-genetic determinants present at the index date were
recorded from the medical charts and extracted from the
prescription histories. We investigated gender, age, duration
of PD, type of non-ergoline DA treatment, concomitant use
of other antiparkinson drugs, daily levodopa dosage, and
concomitant use of antipsychotics and antidepressants. The
mean dosage of non-ergoline DA during follow-up was also
investigated as a determinant for discontinuation.
Genetic determinants for discontinuation of non-ergoline
DA treatment were studied in the subgroup of patients who
gave separate informed consent for genetic testing. Poly-
morphisms in the DRD2 gene and DRD3 gene were
selected based on indications for clinical relevance deter-
mined from previous publications: DRD2 141C Ins/Del
SNP (rs1799732), DRD2 (CA)n STR, DRD2 TaqIA SNP
(rs1800497), DRD3 MscI single nucleotide polymorphism
(SNP) (rs6280) and DRD3 MspI SNP (rs4646996) [8].
Genotyping
Saliva specimens were collected with Oragene-DNA tubes
(DNA Genotek, Kanata, ONT, Canada). Polymerase chain
reaction analyses were performed under standard conditions
on the MyCycler system (Bio-Rad, Veenendaal, The
Netherlands). The Hotstart PCR Mastermix was obtained
from Qiagen (Hilden, Germany). Genotyping was per-
formed according to the protocol provided by the manu-
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Leiden, The Netherlands). Allele frequencies were as
follows: for DRD2 141-C, 72% ins, 28% del; for DRD2
TaqIA (C>T), 71% C, 29% T; for DRD2 (CA)n STR, 13%
13x, 11% 14x, 46% 15x, 29% 16x, 1% 17x; for DRD3
MscI (Ser>Gly), 79% Ser, 21% Gly; for DRD3 MspI
(A>G), 47% A (absence), 54% G (presence). The allele
frequencies were in accordance with those reported in the
literature [8]. The genotype frequencies were in Hardy–
Weinberg equilibrium, and the genotyping success rate was
100.0%. A linkage disequilibrium was found between
DRD2 ins/del and the DRD2 TaqIA genotype (r
2=0.937).
Data analysis
Fisher’s exact test was used to test differences in dichoto-
mous variables, and Student’s t-test was used for continu-
ous variables. Cox proportional hazard analysis was used to
estimate the hazard ratios (HR) for the discontinuation of
non-ergoline DA treatment. Cumulative hazards for dis-
continuation were plotted against the time of follow-up. In
the genetic analyses, alleles were combined because of the
relative low numbers in the genetic subgroup.
All analyses were performed using SPSS ver. 12.0
(SPSS, Chicago, IL).
Results
Description of the cohort
Clinical characteristics of the cohort are described in
Table 1. The overall study population consisted of 90
patients who were first-time users of a non-ergoline DA
treatment; 50% were ropinirole starters and 50% were
pramipexole starters. The mean follow-up period was
28.7 months. DNA samples for an exploratory pharmaco-
genetic analysis were available for 38 patients. The flow-
chart of inclusion in the genetic analysis subgroup is
presented in Fig. 1. Compared to the total cohort, patients
for whom DNA was available were younger (63.4 vs.
69.8 years; p<0.001) and had a shorter disease duration
(4.4 vs. 7.4 years; p=0.022).
In the overall population, there was a large range in
mean daily DA dosage during follow-up: from 0.17 to 6.64
defined daily dosages (DDD). However, most patients
used <1.5 DDD (81.1%).
Discontinuation
Of the patients in our study who started on non-ergoline
DA treatment, 35.6, 51.1 and 55.6% discontinued this
therapy after 1, 3 and 5 years, respectively. Of the patients
in the subgroup for pharmacogenetic analysis, 31.6, 47.4
and 52.6% discontinued non-ergoline DA treatment after 1,
3 and 5 years, respectively. Treatment discontinuation was
confirmed by 18 of the 20 patients in the genetic subgroup.
In all cases, discontinuation was initiated by the neurologist
and were based on insufficient response (four patients,
22.2%) and side effects (nine patients, 50.0%). Five
patients (27.8%) could not recall the reason of discontin-
uation. The side effects that were the basis for discontin-
uation are summarized in Table 2.
Non-genetic determinants associated with non-ergoline
DA discontinuation
The results of the Cox regression analysis are presented in
Table 3. All 90 patients were included in this analysis.
Apomorphine use was associated with non-ergoline DA
discontinuation [HR 6.26; 95% confidence interval (CI)
1.85–21.2]. However, the apomorphine group consisted
only of three patients. The use of levodopa resulted in
conflicting data in that its actual use was not associated
with discontinuation, but within the levodopa users,
dosages between 500 and 1000 mg were positively
associated with discontinuation (HR 2.31; 95% CI 1.08–
4.93). Higher dosages of non-ergoline DA were associated
with less treatment discontinuation over time (HR for ≥0.75–
1.50 DDD 0.39; 95% CI 0.20–0.75; HR for ≥1.50 DDD
0.39; 95% CI 0.17–0.88).
Genetic determinants associated with non-ergoline
DA discontinuation
The results of the Cox regression analysis of genetic
determinants, carried out on 38 patients, are presented in
Table 4. The absence of a 15× DRD2 CA repeat allele was
related to a decreased discontinuation of non-ergoline DA
treatment (HR 0.23; 95% CI 0.07–0.81). Patients with the
DRD3 MspI G allele (presence of MspI restriction site) had
a non-significant twofold higher risk of non-ergoline DA
treatment discontinuation (95% CI 0.61–7.17). The DRD3
MspI polymorphism showed an allele dose effect (increase
in risk per G allele), which is suggestive of a causal
relationship with discontinuation (A/A: ref; A/G: HR 1.56;
95% CI 0.42–5.77; G/G: HR 3.50; 95% CI 0.91–13.4). No
other statistically significant associations between genetic
polymorphisms and non-ergoline DA treatment discontin-
uation were detected.
Discussion
This study identified non-genetic and genetic determinants
for discontinuation of the non-ergoline DA ropinirole and
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associated with discontinuation were apomorphine use,
levodopa dosage, and the dosage of non-ergoline DA
during follow-up. In an exploratory pharmacogenetic
analysis, we identified a DRD2 (CA)n repeat polymorphism
that was associated with non-ergoline DA discontinuation.
Apomorphine use was associated with a sixtime higher
risk of discontinuation. Apomorphine is a potent DA and is
used in patients with severe on–off fluctuations. As other,
less potent dopaminergic drugs can be discontinued with
the initiation of apomorphine therapy, it is not surprising
that apomorphine use is associated with non-ergoline DA
treatment discontinuation. More than half of the patients
included in this study used levodopa when starting non-
ergoline DA treatment. One might expect that higher
levodopa dosages have a higher risk of dopaminergic side
effects, often resulting in the discontinuation of other
dopaminergic treatment. This is in line with our findings.
The use of levodopa itself was not associated with non-
ergoline DA discontinuation, but within the levodopa users,
dosages between 500 and 1000 mg were positively
associated with non-ergoline DA discontinuation. However,
as levodopa dosages >1000 mg were not associated with
non-ergoline DA discontinuation, this result may have been
an artefact due to the relatively small numbers of patients
that used >1000 mg levodopa per day.
Table 1 Baseline characteristics of the study cohort
Baseline demographic/clinical characteristics of study population Overall population
(n =90)
Genetic analysis
subgroup (n =38)
p value
a
Male gender 49 (54.4) 25 (65.8) 0.087
Mean age in years (SD); range 67.8 (8.7); 48–91 63.4 (6.9); 49–78 <0.001
<65 years 29 (32.2) 21 (55.3) 0.001
≥65 years 61 (67.8) 17 (44.7)
Mean duration of PD in years, (range) 6.2; 0–39.3 4.4; 0–16.2 0.022
<5 years 47 (52.2) 21 (55.3) 0.673
≥5 years 43 (47.8) 17 (44.7)
Mean follow-up in months; range 28.7; 0.4–91.0 32.0; 0.4–91.0 0.288
Non-ergoline dopamine agonist treatment
Ropinirole 42 (46.7) 19 (50.0) 0.671
Pramipexole 48 (53.3) 19 (50.0)
Concomitant use of other antiparkinsonian drugs at index date
Amantadine 17 (18.9) 10 (26.3) 0.173
Selegeline 7 (7.8) 2 (5.3) 0.694
Apomorphine 3 (3.3) 1 (2.6) 0.617
Other dopamine agonist 1 (1.1) 0 (0) 1.000
Levodopa 57 (63.3) 19 (50.0) 0.029
Mean daily levodopa dosage at index date in milligrams (SD); range 466 (331); 100–1804 422 (280); 149–1302 0.485
<500 mg 40 (70.2) 14 (73.7) 0.906
≥500 mg–1000 mg 12 (21.1) 4 (21.1)
≥1000 mg 5 (8.8) 1 (5.3)
Concomitant use of other medication at index date
Antipsychotics 12 (13.3) 5 (13.2) 1.000
Antidepressants 6 (6.7) 3 (7.9) 0.694
Mean daily dopamine agonist dosage in DDD
b (SD); range 1.17 (1.08); 0.17–6.64 1.13 (0.89); 0.18–3.91 0.787
<0.75 DDD 41 (45.6) 19 (50.0) 0.273
≥0.75–1.50 DDD 32 (35.6) 10 (26.3)
≥1.50 DDD 17 (18.9) 9 (23.7)
Values are given as the number (n), with the percentage in parenthesis, unless stated otherwise
PD, Parkinson's disease; DDD, defined daily dose; SD, standard deviation
ap value between patients within genetic analysis subgroup vs. those not within genetic analysis subgroup (not shown). The Fisher’s exact test for
dichotomous variables and Student’s t-test for continuous variables were used
bMean of entire follow-up period. 1 DDD ropinirole=6.0 mg; 1 DDD pramipexole=2.5 mg
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ated with a reduced chance of treatment discontinuation.
This can be explained by the fact that the dosage of these
drugs is slowly increased in order to minimize adverse
events and by the fact that most patients discontinued in the
first months after treatment initiation [9]. Thus, this
association is a marker for early discontinuation.
We hypothesized that genetic polymorphisms in the
genes encoding the DR, specifically in DRD2 and DRD3,
could be associated with discontinuation of DA use.
Indeed, our data show interesting genetic results. The
absence of a 15× DRD2 CA repeat allele was associated
with a decreased risk of non-ergoline DA treatment
discontinuation. The DRD2 (CA)n polymorphism is located
in a non-coding region of the DRD2 gene, but the precise
functional consequence of this polymorphism for the DRD2
protein remains unclear. The DRD3 MspI polymorphism
showed an allele dose effect (increase in the risk of
treatment discontinuation per G allele), which is suggestive
of a causal relationship. The consequence of this polymor-
phism on DRD3 functionality remains to be unraveled. The
DRD3 MspI polymorphism is located in an intron,
suggesting no direct influence of the polymorphism on
DRD3 protein function, and is near the MscI polymor-
phism. However, we found no linkage disequilibrium
between these two polymorphisms. It may be that the
non-significant association between the DRD3 MspI poly-
morphism and non-ergoline DA treatment discontinuation
is indicative of other polymorphisms not studied in this
gene region. Although we expected that the DRD3 MscI
Gly polymorphism would lead to increased agonist binding
[7, 10], we did not notice an association between this
polymorphism and non-ergoline DA discontinuation. Wang
and colleagues found that PD patients with the DRD2
TaqIA polymorphism who received levodopa had a higher
risk of developing motor fluctuations [11]. Again, we did
not find an effect of this polymorphism on DA discontin-
uation. Our finding may not be surprising as the DRD2
Table 2 Reported reasons for discontinuation of non-ergoline DA
treatment in the genetic analysis subgroup
Clinical basis for discontinuation of non-ergoline
DA treatment
Genetic analysis
subgroup (n=38)
Patients that discontinued non-ergoline
DA treatment
20 (52.6)
Confirmed by patient 18 (90.0)
Discontinuation initiated by:
Neurologist 18 (100.0)
Reasons for discontinuation
Lack of sufficient response 4 (22.2)
Side effects
a 9 (50.0)
Excessive daytime sleepiness
a 3
Hallucinations or psychosis 2
Nausea 1
Lightheadedness or dizziness 1
Hypersexuality
a 1
Dopaminergic drug abuse
a 1
Diarrhoea 1
Eczema 1
Patient can not recall reason 5 (27.8)
Values are given as the number (n), with the percentage in parenthesis
DA, Dopamine agonist
aOne patient reported three side effects.
90 patients from previous study included 
in non-genetic analysis
15 patients already deceased
75 patients asked consent
32 patients no consent:
- 3 patients were deceased
- 16 patients denied consent
- 13 patients did not respond
43 patients gave consent
4 patients were not able to 
participate
39 patients participated
1 patient not able to collect DNA
38 patients included in genetic analysis
Fig. 1 Flow-chart of inclusion
genetic analysis subgroup
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the ankyrin repeat and kinase domain containing 1
(ANKK1), which is located downstream of the DRD2
gene. It is therefore unlikely that this polymorphism alters
DRD2 activity directly.
Several remarks should be made with respect to the
methodology used. In this study, use of the non-ergoline
DA ropinirole and pramipexole was combined in order to
improve statistical power. This can be justified by the fact
that both ropinirole and pramipexole are DRD2 agonists
with a preferential affinity for the DRD3 subgroup. The
choice of the endpoint of this study, discontinuation of non-
ergoline DA treatment, which encompasses both efficacy
and tolerability, is also open to discussion. Since discon-
tinuation related to insufficient efficacy and to intolerability
may be mechanistically different, ideally, a stratified
analysis on separate endpoints efficacy and tolerability
should be performed. However, this could not be done
because the reasons for discontinuation in the overall
population were not known and because the population in
the genetic analysis was too small for subgroup analysis.
Moreover, the baseline characteristics in the genetic
analysis subgroup differed from those of the overall study
population due to the fact that there was a time gap of
nearly 2 years between the selection of the overall
population and receiving informed consent from patients
for the pharmacogenetic analysis. Fortunately, the allele
frequencies were in accordance with those reported in the
literature [8]. We did not correct for multiple testing as the
aim of the genetic subgroup study was to perform an
exploratory analysis of genetic determinants. Positive
associations should therefore be interpreted with caution.
Finally, we included outpatients from only one hospital.
Therefore, the results could have been biased by the
prescribing patterns of a few clinicians.
Table 3 Hazard ratios for discontinuation of non-ergoline DA
treatment in overall population
Demographic/clinical characteristics Crude HR,
n =90
Gender
Male Reference
Female 0.75 (0.43–1.31)
Age
<65 years Reference
≥65 years 1.04 (0.57–1.91)
Duration of PD
<5 years Reference
≥5 years 0.81 (0.46–1.41)
Treatment
Ropinirole Reference
Pramipexole 1.15 (0.66–2.02)
Concomitant use of other antiparkinsonian
drugs at index date (%)
a
Amantadine 0.76 (0.36–1.62)
Selegeline 0.97 (0.35–2.71)
Apomorphine
b 6.26 (1.85–21.2)
Other dopamine agonist 0.05 (0–702)
Levodopa 1.26 (0.70–2.28)
Daily levodopa dosage at index date
<500 mg Reference
≥500 mg–1000 mg
b 2.31 (1.08–4.93)
≥1000 mg 1.59 (0.47–5.37)
Concomitant use of other medication
at index date (%)
a
Antipsychotics 0.62 (0.25–1.57)
Antidepressants 0.68 (0.21–2.18)
Daily dopamine agonist dosage
c
<0.75 DDD Reference
≥0.75–1.50 DDD
b 0.39 (0.20–0.75)
≥1.50 DDD
b 0.39 (0.17–0.88)
Values are given as the hazard ratio (HR), with the 95% confidence
interval (CI) in parenthesis
aPresence vs. absence (Reference)
bFactors associated with non-ergoline DA discontinuation
cMean of entire follow-up period: 1 DDD ropinirole=6.0 mg; 1 DDD
pramipexole=2.5 mg (as established by the World Health Organiza-
tion Collaborating Centre for Drug Statistics Methodology)
Table 4 Hazard ratios for discontinuation of non-ergoline DA
treatment in genetic analysis subgroup
Genotype Genetic analysis
subgroup (n =38)
a
Crude HR (95%CI)
DRD2 141-C ins/del
Ins/Ins 20 (52.6) Reference
Ins/Del + Del/Del 18 (47.4) 1.00 (0.42–2.42)
DRD2 Taq1A (C>T)
C/C 19 (50.0) Reference
C/T + T/T 19 (50.0) 0.84 (0.35–2.04)
DRD2 (CA)n STR
15× allele 26 (68.4) Reference
No 15× allele
b 12 (31.6) 0.23 (0.07–0.81)
DRD3 MscI (Ser>Gly)
Ser/Ser 24 (63.2) Reference
Ser/Gly + Gly/Gly 14 (36.8) 0.79 (0.31–1.98)
DRD3 MspI (A>G) (absence > presence of restriction site)
A/A 8 (21.1) Reference
A/G + G/G 30 (78.9) 2.09 (0.61–7.17)
aValues are given as the number (n) of patients, with the percentage in
parenthesis
bThe absence of a 15× DRD2 CA repeat allele was associated with a
decreased discontinuation of non-ergoline DA treatment
1250 Eur J Clin Pharmacol (2009) 65:1245–1251The study reported here is the first to investigate
determinants for the discontinuation of non-ergoline DA
therapy, including pharmacogenetic determinants. Ideally,
knowledge of these determinants will enable clinicians to
predict an individual’s response.
In conclusion, we have identified non-genetic (apomor-
phine use and daily levodopa dosages between 500 and
1000 mg) and genetic determinants [DRD2 (CA)n repeat
polymorphism] for the discontinuation of non-ergoline DA
treatment. The DRD3 MspI polymorphism also showed a
non-significant allele dose effect with non-ergoline DA
treatment discontinuation, which is suggestive of a causal
relationship. Confirmation of these data is warranted.
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